Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
  • Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency.

Thumbnail
View/Open
Published version (4.534Mb)
Date
2021-11-08
ICR Author
Pettitt, Stephen
Lord, Christopher
Tutt, Andrew
Haider, Syed
Wicks, Andrew
Author
Bajrami, I
Walker, C
Krastev, DB
Weekes, D
Song, F
Wicks, AJ
Alexander, J
Haider, S
Brough, R
Pettitt, SJ
Tutt, ANJ
Lord, CJ
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
PARP enzymes utilise NAD+ as a co-substrate for their enzymatic activity. Inhibition of PARP1 is synthetic lethal with defects in either BRCA1 or BRCA2. In order to assess whether other genes implicated in NAD+ metabolism were synthetic lethal with BRCA1 or BRCA2 gene defects, we carried out a genetic screen, which identified a synthetic lethality between BRCA1 and genetic inhibition of either of two sirtuin (SIRT) enzymes, SIRT1 or SIRT6. This synthetic lethal interaction was replicated using small-molecule SIRT inhibitors and was associated with replication stress and increased cellular PARylation, in contrast to the decreased PARylation associated with BRCA-gene/PARP inhibitor synthetic lethality. SIRT/BRCA1 synthetic lethality was reversed by genetic ablation of either PARP1 or the histone PARylation factor-coding gene HPF1, implicating PARP1/HPF1-mediated serine ADP-ribosylation as part of the mechanistic basis of this synthetic lethal effect. These observations suggest that PARP1/HPF1-mediated serine ADP-ribosylation, when driven by SIRT inhibition, can inadvertently inhibit the growth of BRCA-gene mutant cells.
URI
https://repository.icr.ac.uk/handle/internal/4883
DOI
https://doi.org/10.1038/s42003-021-02770-2
Collections
  • Breast Cancer Research
  • Molecular Pathology
Research team
Gene Function
Language
eng
Date accepted
2021-10-06
License start date
2021-11-08
Citation
Commun Biol, 2021, 4 (1), pp. 1270 - ?

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.